CD274 and neoplasm: To date, the U.S. Food and Drug Administration has approved three classes of ICIs, targeting CTLA-4, PD-1/PD-L1, and LAG-3, with additional agents in development across over 20 tumor types in the neoadjuvant, adjuvant, and metastatic settings.